Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria

BMC Research Notes

Kinsley Aile¹  Seun Ilori³  Kikelomo O Wright⁴  Sulaiman Akanmu²  Adewumi Adediran²  Titilope A Adeyemo²  Owolabi A Dosunmu¹  Olajumoke O Oshinaike⁵  Akinsegun A Akinbami¹ 

[1] Department of Haematology and Blood Transfusion, Lagos State University College of Medicine, Ikeja, Nigeria;Department of Haematology and Blood Transfusion, Faculty of Clinical Sciences, College of Medicine, Idiaraba, Lagos, Nigeria;APIN Clinic, Lagos University Teaching Hospital. Idiaraba, Lagos, Nigeria;Department of Community Health and Primary Health Care, Lagos State University College of Medicine, Ikeja, Nigeria;Department of Internal Medicine, Lagos State University College of Medicine, Ikeja, Nigeria

关键词: Blood donors;    IgM anti-HBc;    IgG anti-HBc;    HBsAg;    HBeAg;    Seroprevalence;   

Others  :  1166542
DOI  :  10.1186/1756-0500-5-167

 received in 2011-10-19, accepted in 2012-03-28,  发布年份 2012

【 摘 要 】

Background

Hepatitis B virus (HBV) is a common cause of liver disease throughout the world. HBV is transmitted through blood and other body fluids, including semen and saliva. Chronic replication of HBV virons is characterized by persistence circulation of HBsAg, HBeAg and HBV DNA; usually with anti-HBc and occasionally with anti-HBs. Aim: To determine the prevalence of HBeAg, IgG anti-HBcore and IgM anti-HBcore amongst HBsAg positive blood donors. These parameters are reflective of transmissibility and active hepatitis B infection. A cross sectional study was carried out at the blood donor clinics of Lagos State University Teaching Hospital Ikeja and Lagos University Teaching Hospital Idiaraba. A total of 267 donors were recruited to determine HBe antigen, IgG and IgM anti-HBcore antibodies amongst hepatitis BsAg positive donors. Five milliliters of blood was collected from those who tested positive to HBsAg screen during donation. The sera were subjected to enzyme linked immunosorbent assay (ELISA). Pearson chi-squared test was used for the analytical assessment.

Findings

A total number of 267 HBsAg positive blood donors were studied. A seroprevalence of 8.2% (22 of 267) HBeAg was obtained, 4 of 267 (1.5%) were indeterminate while 241 (90.3%) tested negative. Only 27 out of 267 donors (10.1%) tested positive to IgM anti-HBcore, 234(87.6%) tested negative, while 6(2.2%) were indeterminate. A higher percentage of 60.7% (162 of 267) tested positive to IgG anti-HBcore, while 39.3% (105 of 267) tested negative.

Conclusion

There is a low seroprevalence rate of HBeAg-positive chronic hepatitis and relatively high IgG anti-HBcore and IgM anti-HBcore rates in South West Nigeria.

【 授权许可】

   
2012 Akinbami et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lok AS: Chronic hepatitis B. N Eng J Med 2002, 346:1682-1683.
• [2]Ott MJ, Aruda M: Hepatitis B vaccine. J Pediatr Health Care 1999, 13:211-6.
• [3]Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2001, 34:1225-41.
• [4]World Health Organization fact sheets no 2004. available at http://who.int/mediacentre/factsheets/fs204/en webcite
• [5]Zuckerman JN, Zuckerman AJ: The epidemiology of hepatitis B. Clin Liver Dis 1999, 3:179-187.
• [6]Fakunle YM, Abdurahman MB, Whittle HC: Hepatitis B virus Infection in Children and Adults in Northern Nigeria: a preliminary Survey. Trans Roy Soc Trop Med Hyg 1981, 75:626-629.
• [7]Abiodun PO, Omoike IU: Hepatitis B surface Antigenaemia in children in Benin City Nigeria. Nig J Paediatr 1990, 17:27-31.
• [8]Ayoola EA, Adelaja AB: Sub-determinants and incidence of Hepatitis B antigen in carriers of HBsAg. Nig Med Practitioner 1986, 11(5/6):133-136.
• [9]Olumide EA: The distribution of HbsAg in Africa and the Tropics: Report of a population study in Nigeria. Int J Epidemiol 1976, 5(3):279-289.
• [10]Kim WR, Brown RS, Terrault NA, El-Seragg HH: Burden of liver disease in the United States: summary of a worhshop. Hepatology 2002, 36:227-242.
• [11]Smith JA, Francis TI, Uriri NO: Australian antigen in blood donors in Ibadan, Nigeria: prevalence and genetic studies. Ghana Med J 1972, 11:43-49.
• [12]Tribedi BB: Australian Antigen in blood donors in Zaria. Nig Med J 1974, 4:127-131.
• [13]Abiodun PO, Ihongbe JC, Ubaru R: HBsAg and Blood donors in Benin City, Nigeria. East Afr Med J 1985, 62:885-887.
• [14]Udeozo IOK, Ele E: The Prevalence of Australian Antigenaemia in Enugu, Nigeria. Nigeria Med J 1974, 4:127-132.
• [15]Ejele OA, Ojule AC: The prevalence of hepatitis b surface Antigen (HBsAg) among prospective blood donors and patients in Port Harcourt, Nigeria. Niger J Med 2004, 13:336-338.
• [16]Ganem D, Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004, 350:11.
• [17]Vinay Kumar , Abul KA, Fausto N, Robins and Contran: Pathological basis of Disease: 6th edition. Edited by John F. Elsevier Inc 2005,1600, Kennedy Boulverd, Suite 1800, Philadephia, PA 19103-2899, USA; 2002.
• [18]Ijeoma S, Nwokediuko , Onyenekwe B, Ijeoma C: Low prevalence of hepatitis Be antigen in asymptomatic adult subjects with hepatitis B virus infection in Enugu, south east Nigeria. Internet J Gastroentorol 2010, 10:1.
• [19]Otegbayo JA, Fasola FA, Abia A: Prevalence of hepatitis B surface and e- antigens, risk factors for virus acquisition and serum transaminase among blood donors in Ibadan. Nigeria Trop Gastroenterol 2003, 24:196-197.
• [20]Abiodun PO, Olomu A, Okolo SN, Obasohan A, Freeman O: The prevalence of Hepatitis Be antigen and anti HBe in adults in Benin City. West Afr J Med 1994, 13:171-174.
• [21]Cohen J: Statistical Power analysis for behavioural sciences. 2nd edition. Lawrence Erlbaum Associates, Hillsdale NJ; 1998.
• [22]Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio P: Chronic Hepatitis B in Italy: new features of an old disease. Approaching the universal prevalence of Hepatitis Be Antigen negative cases and the eradication of Hepatitis D infection. Clin Infec Dis 2008, 46(1):110-113.
• [23]Funk ML, Roseberg DM, Lok AS: Worldwide epidermiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002, 9:52-61.
• [24]Chan HL, Leung NW, Hussain M, Wong ML, Lok AS: Hepatitis Be antigen negative chronic hepatitis in Hong Kong. Hepatology 2000, 3(13):763-764.
• [25]Hadziyannis SJ, Papatheodoridis GC, Vassilopoulos D: Traetment of HBeAg-negative chronic hepatitis B. Semin Live Dis 2003, 23:81-88.
• [26]Laras A, Koskinas J, Avigidis K, et al.: Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e anigen-negative patients. J Viral Hepat 1998, 5:241-248.
• [27]Fattovich G: Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47-58.
• [28]Sheikh NS, Sheikh AS, Sheikh AA, Yahya S, Rafi-U-Shan , Lateef M: Sero-prevalence of Hepatitis B Virus infection in Balochistan province of Pakistan. Saudi. J Gastroenterol 2011, 17:180-4.
• [29]Lavarini C, Farci P, Chiaberge E, Veglio E, Giarcbbiet D, et al.: IgM antibody against hepatitis B core antigen (IgM anti-HBc): diagnostic and prognostic significance in acute HBsAg positive hepatitis. Brit Med J 1983, 287:1254-1256.
• [30]Bawazir AA, Parry CM, Hart CA, Sallam TA, Beeching N: Seroepidermiology and risk factors of hepatitis B virus in Aden, Yemen. J Infec Pub Health 2011, 4(1):48-54.
• [31]Seo DH, Whang DH, Song EY, Kim HS, Park Q: Prevalence of antibodies of hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion 2011, 51(8):1840-1846.
• [32]Antar W, Elholary MH, Abd EL, Hamid WA, Helmy MF: Significance of detecting anti-HBc among Egyptian male blood donors negative for HBsAg. Trans Med 2010, 20(6):409-413.
• [33]Findik D, Arslan U, Baykan M: Determination of hepatitis B virus DNA incidence, viral load, and mutations in blood donors with HBsAg-negative serology and antibodies to hepatitis B core antigen. Eur J Intern Med 2007, 18(8):571-5.
• [34]Lavanchy D: Hepatitis B virus epidermiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.